AGRX - Agile Therapeutics: Taking A Victory Lap While We Wait For Twirla's Commercial Launch
Agile Therapeutics (AGRX) struggled for years to get their once-weekly contraceptive patch, Twirla, approved by the FDA. Twirla received two CRLs from the FDA, which pummeled the share price into penny stock status, and investors' sentiment was abysmal. For two years, it looked as if the FDA was not going to give Twirla the green light. After appeasing the FDA's Division of Bone, Reproductive, and Urologic Products "DBRUP" with finish their comparative wear study and fighting through an AdCom, the company eventually received FDA approval. Now, the stock is trading above $3.00 per share as